Correia Marcelo L G, Haynes William G
Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA.
Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. doi: 10.1517/14728214.10.3.643.
Obesity is associated with hypertension, diabetes, dyslipidaemias and metabolic syndrome, and causes substantial morbidity and mortality from cardiovascular and other diseases. The cost to treat obesity and its complications in the US has increased steeply and is currently estimated to be USD 100 billion. Current therapy for obesity is mainly based on changes in lifestyle that often fail. Existing pharmacological treatment is marginally efficient and poorly tolerated. The discovery of leptin and related neural mechanisms of energy metabolism regulation has opened the doors to potential targets for new antiobesity drugs. In this review, new pharmacological targets are discussed and an update on the development of emerging antiobesity drugs is provided. Despite intense investigation, the pipelines for antiobesity drugs in late stages of development are relatively empty. Breakthrough treatments for obesity may take some years to emerge. Clinical trials will be necessary to clarify the impact of new antiobesity drugs on hard cardiovascular and metabolic end points.
肥胖与高血压、糖尿病、血脂异常及代谢综合征相关，会导致心血管疾病和其他疾病引发大量发病和死亡情况。在美国，治疗肥胖及其并发症的费用急剧增加，目前估计达1000亿美元。当前的肥胖治疗主要基于往往无效的生活方式改变。现有的药物治疗效果甚微且耐受性差。瘦素的发现以及能量代谢调节的相关神经机制为新型抗肥胖药物的潜在靶点打开了大门。在本综述中，讨论了新的药理学靶点，并提供了新兴抗肥胖药物研发的最新情况。尽管进行了深入研究，但处于研发后期的抗肥胖药物产品线相对匮乏。肥胖的突破性治疗可能还需要数年时间才能出现。有必要通过临床试验来阐明新型抗肥胖药物对心血管和代谢硬终点的影响。
